GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) have been given an average rating of “Moderate Buy” by the fifteen ratings firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, nine have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $8.86.

A number of equities research analysts have weighed in on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $10.00 target price on shares of GoodRx in a report on Friday, August 16th. Barclays dropped their target price on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Monday, November 11th. Citigroup dropped their target price on shares of GoodRx from $10.00 to $7.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. Raymond James upgraded shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price objective on the stock in a report on Friday, August 9th. Finally, UBS Group lowered their price objective on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a report on Friday, August 9th.

GoodRx Trading Down 0.4 %

Shares of GoodRx stock opened at $4.84 on Wednesday. GoodRx has a 1 year low of $4.09 and a 1 year high of $9.26. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $1.84 billion, a PE ratio of -161.33, a price-to-earnings-growth ratio of 3.52 and a beta of 1.39. The firm’s 50 day moving average is $5.98 and its 200 day moving average is $7.25.

Insider Activity at GoodRx

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total transaction of $83,921.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.17% of the stock is owned by company insiders.

Hedge Funds Weigh In On GoodRx

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rubric Capital Management LP lifted its holdings in shares of GoodRx by 25.2% in the third quarter. Rubric Capital Management LP now owns 4,680,028 shares of the company’s stock worth $32,479,000 after buying an additional 943,226 shares in the last quarter. Millennium Management LLC grew its holdings in shares of GoodRx by 36.5% in the second quarter. Millennium Management LLC now owns 4,121,939 shares of the company’s stock worth $32,151,000 after purchasing an additional 1,102,758 shares during the last quarter. American Century Companies Inc. bought a new position in shares of GoodRx in the second quarter worth approximately $18,183,000. Point72 Asset Management L.P. bought a new stake in GoodRx in the third quarter valued at $11,295,000. Finally, Geode Capital Management LLC boosted its holdings in GoodRx by 6.3% in the third quarter. Geode Capital Management LLC now owns 982,729 shares of the company’s stock valued at $6,823,000 after acquiring an additional 58,610 shares in the last quarter. Institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.